camptothecin has been researched along with Obesity in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H; Lu, JF; Shi, XC; Wu, JW; Xia, B; Xie, BC; Zhang, RX; Zhu, MQ | 1 |
| Akagi, Y; Baba, H; Emi, Y; Maehara, Y; Miyamoto, Y; Ogata, Y; Oki, E; Saeki, H; Sakamoto, Y; Shimokawa, M; Tanaka, T; Tokunaga, S | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Gandhi, A; Ghose, R; Mallick, P; Shah, P | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
1 review(s) available for camptothecin and Obesity
| Article | Year |
|---|---|
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
1 trial(s) available for camptothecin and Obesity
| Article | Year |
|---|---|
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
4 other study(ies) available for camptothecin and Obesity
| Article | Year |
|---|---|
Camptothecin effectively treats obesity in mice through GDF15 induction.
Topics: Animals; Body Weight; Camptothecin; Cell Line; Cell Line, Tumor; Diet, High-Fat; Eating; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor Receptors; Growth Differentiation Factor 15; HEK293 Cells; HL-60 Cells; Humans; Male; MCF-7 Cells; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; PC-3 Cells | 2022 |
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intra-Abdominal Fat; Leucovorin; Male; Middle Aged; Obesity; Organoplatinum Compounds; Retrospective Studies; Young Adult | 2018 |
Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Feces; Glucuronates; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |